Exact Therapeutics (Norway) Performance
| EXTX Stock | NOK 3.78 0.06 1.56% |
The firm shows a Beta (market volatility) of 0.31, which means possible diversification benefits within a given portfolio. As returns on the market increase, Exact Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Exact Therapeutics is expected to be smaller as well. At this point, Exact Therapeutics has a negative expected return of -0.42%. Please make sure to confirm Exact Therapeutics' mean deviation, jensen alpha, potential upside, as well as the relationship between the standard deviation and treynor ratio , to decide if Exact Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Exact Therapeutics AS has generated negative risk-adjusted returns adding no value to investors with long positions. Despite conflicting performance in the last few months, the Stock's essential indicators remain quite persistent which may send shares a bit higher in January 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
| Begin Period Cash Flow | 139.2 M | |
| Total Cashflows From Investing Activities | -1 M | |
| Free Cash Flow | -56.7 M |
Exact |
Exact Therapeutics Relative Risk vs. Return Landscape
If you would invest 550.00 in Exact Therapeutics AS on September 12, 2024 and sell it today you would lose (172.00) from holding Exact Therapeutics AS or give up 31.27% of portfolio value over 90 days. Exact Therapeutics AS is generating negative expected returns and assumes 5.2376% volatility on return distribution over the 90 days horizon. Simply put, 46% of stocks are less volatile than Exact, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Exact Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Exact Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Exact Therapeutics AS, and traders can use it to determine the average amount a Exact Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.081
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | EXTX |
Estimated Market Risk
| 5.24 actual daily | 46 54% of assets are more volatile |
Expected Return
| -0.42 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Exact Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Exact Therapeutics by adding Exact Therapeutics to a well-diversified portfolio.
Exact Therapeutics Fundamentals Growth
Exact Stock prices reflect investors' perceptions of the future prospects and financial health of Exact Therapeutics, and Exact Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Exact Stock performance.
| Return On Equity | -0.46 | |||
| Return On Asset | -0.26 | |||
| Operating Margin | (844.98) % | |||
| Current Valuation | 432.68 M | |||
| Shares Outstanding | 30 M | |||
| Price To Book | 6.55 X | |||
| Price To Sales | 8,803 X | |||
| EBITDA | (56.66 M) | |||
| Book Value Per Share | 2.60 X | |||
| Cash Flow From Operations | (55.11 M) | |||
| Earnings Per Share | (1.95) X | |||
| Total Asset | 117.63 M | |||
About Exact Therapeutics Performance
By examining Exact Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Exact Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Exact Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
EXACT Therapeutics AS, a clinical stage biotech company, develops a technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy . The company was founded in 2012 and is based in Oslo, Norway. EXACT THERAPEUTICS is traded on Oslo Stock Exchange in Norway.Things to note about Exact Therapeutics performance evaluation
Checking the ongoing alerts about Exact Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Exact Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Exact Therapeutics generated a negative expected return over the last 90 days | |
| Exact Therapeutics has high historical volatility and very poor performance | |
| Exact Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (58.59 M) with profit before overhead, payroll, taxes, and interest of 52 K. | |
| Exact Therapeutics generates negative cash flow from operations | |
| About 64.0% of the company shares are held by company insiders |
- Analyzing Exact Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Exact Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Exact Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Exact Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Exact Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Exact Therapeutics' stock. These opinions can provide insight into Exact Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Exact Stock
Exact Therapeutics financial ratios help investors to determine whether Exact Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Exact with respect to the benefits of owning Exact Therapeutics security.